The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU) who purchased (a) common stock pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about July 23, 2021; and/or (b) securities between July 23, 2021, and December 9, 2022, both dates inclusive. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
(i) the treatment effect of the Company's product candidate, CB-010, was not as durable as defendants had led investors to believe; (ii) accordingly, CB-010’s clinical and commercial prospects were overstated; and (iii) as a result, documents issued in connection with Caribou's initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Shareholders have until April 11, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >